LHRH-a: Luteinizing hormone-releasing hormone agonist; MRC: Medical Research Council; NCIC: National Cancer Insitute of Canada; PCSS: Prostate cancer-specific survival; PSA: Prostate-specific ...

The aim was to compare serum TST recovery between LHRH agonists and LHRH antagonists. A total of 131 patients who underwent radiation therapy with ADT for prostate cancer were retrospectively analyzed ...

LHRH-a: Luteinizing hormone-releasing hormone agonist; MRC: Medical Research Council; NCIC: National Cancer Insitute of Canada; PCSS: Prostate cancer-specific survival; PSA: Prostate-specific ...

An Ancillary Study of the STAMPEDE Docetaxel Trials Ruth Langley presented results from a phase 3 trial comparing transdermal estradiol to LHRH agonists for androgen suppression in M0 prostate cancer.

Patients must have had histological, pathological, and/or cytological confirmation of prostate cancer ... and either prior orchiectomy or be medically castrate using LHRH agonists/antagonists in order ...

Medically reviewed by Matthew Wosnitzer, MD Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer ...

Researchers are warning that men who regularly dodge prostate cancer screening appointments are 45% more likely to die from the disease. Prostate cancer is the most common cancer among men and the ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime. In addition, about 1 in 44 men will die from the ...

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study. Here is a roundup of March 2025 U.S. FDA ...